Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Alkermes Plc(ALKS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALKS
10/23/2026: ALKS (1-star) is currently NOT-A-BUY. Pass it for now.
Alkermes Plc is a specialized biopharmaceutical company that develops and markets proprietary treatments for neuroscience conditions and oncology. Its primary commercial strength lies in its diversified neuroscience portfolio, including LYBALVI, which serves as a key engine for growth. The company's investment story centers on its ability to leverage its drug delivery platforms and expand into the oncology space. However, investors must weigh these opportunities against significant risks, including reliance on a small number of core products, intense competition, and clinical trial uncertainty. The stock is best suited for growth-oriented investors with a high risk tolerance who are capable of monitoring clinical and regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is largely dependent on the successful adoption of newer products like LYBALVI and the clinical outcomes of the oncology pipeline. |
| Momentum investor | Strong fit while signal remains positive | Momentum interest is tied to positive clinical data readouts or exceeding quarterly commercial sales expectations. |
| Value investor | Mixed fit | The valuation depends on long-term pipeline success, which is inherently difficult to price, making it a complex fit for traditional value investors. |
| Dividend investor | Weak fit | Alkermes does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Biotech stocks face inherent clinical and regulatory risks that result in high volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results and regulatory decisions can lead to sharp swings in stock price. |
| Valuation risk | Medium / high | Valuation is sensitive to the success of ongoing clinical programs and market share growth of key products. |
| Competition risk (Pharma/Biotech) | High | Intense competition from established pharmaceutical companies threatens market share and pricing power. |
| Business quality | Medium | The company has a proven commercial engine but relies heavily on a few products, creating product concentration risk. |
| Dividend income | Low / none | No dividend is offered, providing no income cushion. |
| Execution risk | Medium / high | The ability to execute on clinical development and commercial sales targets is critical to long-term success. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -10.55% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.41B USD | Price to earnings Ratio 113.28 | 1Y Target Price 56.21 |
Price to earnings Ratio 113.28 | 1Y Target Price 56.21 | ||
Volume (30-day avg) 2.4M shares | Beta 0.27 | 52 Weeks Range 27.00 - 55.67 | Updated Date 10/22/2026 |
52 Weeks Range 27.00 - 55.67 | Updated Date 10/22/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.39 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue from the sale of proprietary products like LYBALVI, VIVITROL, and ARISTADA. | This is the core revenue driver representing the company's ability to sell its approved drugs to healthcare providers. |
| Royalties and Manufacturing | Revenue from royalties on products licensed to other companies and manufacturing services for third parties. | These are secondary, often declining, revenue streams that rely on the commercial success of partners. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 113.28 | Forward PE 133.33 | Enterprise Value 7.98B | Price to Sales(TTM) 4.44 |
Enterprise Value 7.98B | Price to Sales(TTM) 4.44 | ||
Enterprise Value to Revenue 4.79 | Enterprise Value to EBITDA 36.62 | Shares Outstanding 167.76M | Shares Floating 155.19M |
Shares Outstanding 167.76M | Shares Floating 155.19M | ||
Percent Insiders 1.4 | Percent Institutions 107.78 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.